Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications

Melanoma is one of the most aggressive skin cancers. The 5-year survival rate of stage III melanoma patients ranges from 93% (IIIA) to 32% (IIID) with a high risk of recurrence after complete surgery. The introduction of target and immune therapies has dramatically improved the overall survival, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonella, Luca, Pala, Valentina, Ponti, Renata, Rubatto, Marco, Gallo, Giuseppe, Mastorino, Luca, Avallone, Gianluca, Merli, Martina, Agostini, Andrea, Fava, Paolo, Bertero, Luca, Senetta, Rebecca, Osella-Abate, Simona, Ribero, Simone, Fierro, Maria Teresa, Quaglino, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123895/
https://www.ncbi.nlm.nih.gov/pubmed/33925387
http://dx.doi.org/10.3390/ijms22094561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123895/
https://www.ncbi.nlm.nih.gov/pubmed/33925387
http://dx.doi.org/10.3390/ijms22094561

Ejemplares similares